

Scabies treatment involves the entire household.¹²

Scabies is a highly contagious infestation of the skin caused by a tiny burrowing mite called *Sarcoptes scabiei*. It is also a debilitating and stigmatizing condition that disproportionately affects disadvantaged communities.^{1,2}

Treating household members and other individuals who have had prolonged skin-to-skin contact with a scabies infested person is paramount to achieving a “complete cure” and reducing the likelihood of reinfestation.³⁻⁶

Today, U.S. household composition is diverse:⁷



38%

are households with married couples and children
(headed by age groups 25-44)



19%

are households with single parents and children
(headed by age groups 25-44)



61%

of households are nonfamily—roommates or cohabitants
(headed by age groups <25)

Natroba™ (spinosad) is today's targeted topical therapy for a "complete cure" of scabies.⁸

After more than 30 years of prescribing the same agents (active pharmaceutical ingredients - APIs) for scabies, Natroba™ offers the only targeted topical therapy that meets today's FDA criteria for a "complete cure."^{1,5-7}



Targeting the stratum corneum⁹

Patented formulation drives the active compound to the stratum corneum where mites live, eat and breed.

New standard for efficacy³

All signs and symptoms of scabies (burrows, lesions, pruritus) have been completely resolved and can be confirmed via microscope or dermoscope.

Demonstrated safety and tolerability profile⁸⁻¹⁰

Phase III data: total adverse reactions reported application site irritation (2/0.7%)* and dry skin (1/0.3%).

Lack of documented resistance¹¹

No known published data documenting human mite resistance to the active compound, spinosad.

Patient-directed application⁸

Compliance with a single, full-body application of Natroba™ can deliver a complete cure.

*Application site irritation also includes application site pain and burning sensation.

References: 1. Felmingham C, Tilakaratne D. Overdiagnosis of scabies and overprescribing of scabies treatment in a scabies-endemic region. *Aust J Rural Health*. 2020 Aug;28(4):394-398. 2. Thadanipon K, Anothaisintawee T, Rattanasiri S, Thakkestian A, Attia J. Efficacy, and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials. *J Am Acad Dermatol*. 2019. 3. ParaPRO, LLC & Concentrics Research (2018). A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy and Pharmacokinetics of Natroba™ (spinosad) for the Treatment of Scabies (Clinical Study Protocol, Amd. 6.0, pp. 1-66). 4. Scabies (Sarcoptes Scabiei), Gilson, et al. National Library of Medicine - StatPearls, 2019. 5. Golant AK, Levitt JO. *Pediatr Rev*. 2012;33(1):e1-e12. 6. Chandler DJ, Fuller LC. *Dermatology*. 2019;235(2):79-90. 7. U.S. Census Bureau, 2017 American Community Survey Public Use Microdata Sample (PUMS). 8. Natroba Prescribing Information. 9. Data on file, ParaPRO, LLC. 10. Center for Drug Evaluation and Research. (2020, March). Contact Dermatitis From Topical Drug Products for Cutaneous Application: Human Safety Assessment Guidance for Industry. U.S. Food and Drug Administration. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contact-dermatitis-topical-drug-products-cutaneous-application-human-safety-assessment-guidance>. 11. Khalil S et al. *PLoS Negl Trop Dis*. 2017;11(11): e0005920. 12. Centers for Disease Control and Prevention. (2018, October 31). CDC - Scabies - Treatment. <https://www.cdc.gov/parasites/scabies/treatment.html>.

INDICATION

Natroba™ Topical Suspension is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients four (4) years of age and older.

ADJUNCTIVE MEASURES

- Wash in hot water or dry-clean any bedding, clothing and towels used by anyone having scabies.
- If any member of a household presents with scabies, all household members should be treated with Natroba™ Topical Suspension.

IMPORTANT SAFETY INFORMATION

Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in pediatric patients below the age of 4 years. The safety and effectiveness of Natroba™ Topical Suspension have not been established in pediatric patients less than 4 years of age with scabies infestation. Most common adverse events were: application site irritation (3%)* and dry skin (2%).

*Application site irritation also includes application site pain and burning sensation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

See pocket for Full Prescribing and Patient Information.